CO6341551A2 - Agentes quimioterapeuticos de cannabinoides en combinacion con no cannabinoides (e.g) agentes serm o de alquilaciion) - Google Patents

Agentes quimioterapeuticos de cannabinoides en combinacion con no cannabinoides (e.g) agentes serm o de alquilaciion)

Info

Publication number
CO6341551A2
CO6341551A2 CO10157628A CO10157628A CO6341551A2 CO 6341551 A2 CO6341551 A2 CO 6341551A2 CO 10157628 A CO10157628 A CO 10157628A CO 10157628 A CO10157628 A CO 10157628A CO 6341551 A2 CO6341551 A2 CO 6341551A2
Authority
CO
Colombia
Prior art keywords
cannabinoids
agents
serm
combination
rental
Prior art date
Application number
CO10157628A
Other languages
English (en)
Inventor
Diez Guillermo Velasco
Pastor Manuel Guzman
Mar Lorente
Sofia Torres
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Publication of CO6341551A2 publication Critical patent/CO6341551A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención se relaciona con el uso de uno o más cannabinoides, particularmente THC y/o CBD con un agente quimioterapéutico no cannabinoide en la fabricación de un medicamento para uso en el tratamiento de cáncer. En particular el cáncer a ser tratado es un tumor cerebral, más particularmente un glioma, aún más particularmente un glioblastoma multiforme (GBM). El agente quimioterapéutico no cannabinoide puede ser un modulador selectivo del receptor de estrógeno o un agente alquilante.
CO10157628A 2008-06-04 2010-12-15 Agentes quimioterapeuticos de cannabinoides en combinacion con no cannabinoides (e.g) agentes serm o de alquilaciion) CO6341551A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0810203.0A GB2460672B (en) 2008-06-04 2008-06-04 Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents

Publications (1)

Publication Number Publication Date
CO6341551A2 true CO6341551A2 (es) 2011-11-21

Family

ID=39638156

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10157628A CO6341551A2 (es) 2008-06-04 2010-12-15 Agentes quimioterapeuticos de cannabinoides en combinacion con no cannabinoides (e.g) agentes serm o de alquilaciion)

Country Status (24)

Country Link
US (3) US20110086113A1 (es)
EP (2) EP3213748B1 (es)
JP (2) JP5674649B2 (es)
KR (1) KR20110053944A (es)
CN (1) CN102083426B (es)
AR (1) AR072002A1 (es)
AU (1) AU2009254935B2 (es)
BR (1) BRPI0911384A8 (es)
CA (1) CA2726257C (es)
CO (1) CO6341551A2 (es)
DK (1) DK2320881T3 (es)
ES (2) ES2653200T3 (es)
GB (2) GB2460672B (es)
IL (1) IL209739A0 (es)
MX (1) MX2010013036A (es)
MY (1) MY156264A (es)
NZ (1) NZ589373A (es)
PT (1) PT2320881T (es)
RU (1) RU2543034C2 (es)
SG (1) SG191643A1 (es)
TW (1) TWI469777B (es)
UA (1) UA104589C2 (es)
WO (1) WO2009147438A1 (es)
ZA (1) ZA201008558B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2554592B (en) * 2010-03-12 2018-07-11 Gw Pharma Ltd A glioma treatment Comprising Temozolomide with a mixture of THA and CBD ar a ration of 1:1
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
CN104797267A (zh) 2012-06-26 2015-07-22 德玛医药 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
GB2516814B (en) * 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RS64115B1 (sr) 2014-03-28 2023-04-28 Univ Duke Lečenje kancera dojke upotrebom selektivnih modulatora receptora estrogena
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
US10406186B2 (en) 2015-01-31 2019-09-10 Constance Therapeutics, Inc. Cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
US20170189373A1 (en) * 2015-05-15 2017-07-06 Andrew Hospodor Terpene Control in Scaleable Cannabinoid Medicinal Formulations
CN109310648B (zh) * 2015-10-27 2022-06-03 杰伊制药公司 用于治疗癌症的包含大麻二酚和第二治疗剂的组合物
EP3380096A4 (en) 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2019046850A1 (en) * 2017-09-02 2019-03-07 Scientific Holdings, Llc MODULATORS OF TETRAHYDROCANNABINOL
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
US20220362168A1 (en) * 2019-08-09 2022-11-17 Jay Pharma Inc. Administration regimes of cannabinoids in combination with chemotherapeutics against cancer
WO2021034405A1 (en) * 2019-08-19 2021-02-25 Diverse Biotech, Inc. Platinum complex anti-neoplastic agents comprising a cannabinoid ligand
US11793847B2 (en) 2021-10-26 2023-10-24 Ecofibre USA Inc. Methods of treating endometrial cancer using hemp extract
CA3235080A1 (en) 2021-10-26 2023-04-05 Alexandra M CAPANO Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ES2164584A1 (es) * 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
RU2166948C1 (ru) * 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения глиом с эпилептическим синдромом
AU2001290949A1 (en) * 2000-09-14 2002-03-26 California Pacific Medical Center Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20080057117A1 (en) * 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
IL148244A0 (en) * 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
WO2003091189A1 (en) * 2002-04-25 2003-11-06 Virginia Commonwealth University Cannabinoids
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
AU2006231452B2 (en) * 2005-04-01 2011-05-26 Intezyne Technologies, Inc. Polymeric micelles for drug delivery
US7968594B2 (en) * 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
CA2608399A1 (en) * 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
KR100675281B1 (ko) * 2005-09-05 2007-01-29 삼성전자주식회사 디커플링 캐패시터를 갖는 반도체 소자 및 그 제조방법
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
UA71391U (ru) * 2012-01-05 2012-07-10 Харьковский Государственный Университет Питания И Торговли Способ получения сыра плавленого пастообразного

Also Published As

Publication number Publication date
NZ589373A (en) 2013-05-31
AU2009254935A1 (en) 2009-12-10
GB2475183A (en) 2011-05-11
GB2460672A (en) 2009-12-09
GB201101072D0 (en) 2011-03-09
CA2726257A1 (en) 2009-12-10
GB2460672B (en) 2012-01-04
US20210069333A1 (en) 2021-03-11
EP3213748B1 (en) 2021-08-18
GB2475183B (en) 2011-11-23
CN102083426A (zh) 2011-06-01
IL209739A0 (en) 2011-02-28
CA2726257C (en) 2016-09-13
PT2320881T (pt) 2017-12-22
JP2011522028A (ja) 2011-07-28
BRPI0911384A2 (pt) 2015-12-29
MY156264A (en) 2016-01-29
RU2543034C2 (ru) 2015-02-27
MX2010013036A (es) 2011-02-18
DK2320881T3 (en) 2018-01-02
GB0810203D0 (en) 2008-07-09
US20190099492A1 (en) 2019-04-04
TWI469777B (zh) 2015-01-21
BRPI0911384A8 (pt) 2018-04-03
KR20110053944A (ko) 2011-05-24
US20110086113A1 (en) 2011-04-14
JP5674649B2 (ja) 2015-02-25
EP3213748A1 (en) 2017-09-06
ZA201008558B (en) 2014-11-26
WO2009147438A1 (en) 2009-12-10
TW201002316A (en) 2010-01-16
UA104589C2 (ru) 2014-02-25
JP2015057411A (ja) 2015-03-26
SG191643A1 (en) 2013-07-31
EP2320881A1 (en) 2011-05-18
AR072002A1 (es) 2010-07-28
ES2887084T3 (es) 2021-12-21
AU2009254935B2 (en) 2015-03-19
ES2653200T3 (es) 2018-02-06
CN102083426B (zh) 2015-05-13
EP2320881B1 (en) 2017-09-20
RU2010154672A (ru) 2012-07-20

Similar Documents

Publication Publication Date Title
CO6341551A2 (es) Agentes quimioterapeuticos de cannabinoides en combinacion con no cannabinoides (e.g) agentes serm o de alquilaciion)
CO6382172A2 (es) Efectos antitumorales de combinaciones cannabinoides
AR080454A1 (es) Fitocanabinoides en el tratamiento del cancer
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CR20120619A (es) Métodos de tratamiento de cáncer de vejiga
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CL2011001863A1 (es) Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07).
ECSP12012024A (es) Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados
IN2012DN02018A (es)
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
ECSP13013007A (es) Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
ECSP088823A (es) Quinazolinas para la inhibición de pdk1
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
NI201000156A (es) Compuestos heterocíclicos novedosos y usos de los mismos.
ECSP12011836A (es) Nuevo uso antitumoral de cabazitaxel
MX370507B (es) Composiciones para determinar la resistencia a la terapia del receptor de andrógeno.
UY32085A (es) Inhibidores de cinasa y métodos para su uso
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
UY29250A1 (es) Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
CL2012000333A1 (es) Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico.

Legal Events

Date Code Title Description
FC Application refused